Skip to main content
Top
Published in: Journal of Hematology & Oncology 1/2012

Open Access 01-12-2012 | Letter to the Editor

The significance of 18F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosis

Authors: Li-Juan Zhang, Ji Xu, Peng Liu, Chong-Yang Ding, Jian-Yong Li, Hong-Xia Qiu, Su-Jiang Zhang

Published in: Journal of Hematology & Oncology | Issue 1/2012

Login to get access

Abstract

This study was aimed to investigate the significance of 18F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosis (sHLH) patients. A total of 18 patients received 18F-FDG PET/CT scan at initial diagnosis. All patients (18/18) had at least 3 organs involved, with increased FDG metabolism in different degrees. Fifteen cases (15/18) had definite underlying diseases, including infections (IAHLH), rheumatosis (RAHLH), or malignancy (MAHLH). The SUVmax of patients in MAHLH group was significantly higher than patients in IAHLH group or RAHLH group (P = 0.015, P = 0.045). Furthermore, the SUVmax of patients in IAHLH group was significantly higher than patients of RAHLH group (P = 0.043). Therefore, we concluded that 18F-FDG PET/CT may especially play important role in differential diagnosis of sHLH.
Appendix
Available only for authorised users
Literature
1.
go back to reference Janka G, Imashuku S, Elinder G: Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998, 12: 435-444. 10.1016/S0889-8588(05)70521-9.CrossRefPubMed Janka G, Imashuku S, Elinder G: Infection- and malignancy-associated hemophagocytic syndromes. Secondary hemophagocytic lymphohistiocytosis. Hematol Oncol Clin North Am. 1998, 12: 435-444. 10.1016/S0889-8588(05)70521-9.CrossRefPubMed
3.
go back to reference Dhote R, Simon J, Papo T: Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003, 49: 633-639. 10.1002/art.11368.CrossRefPubMed Dhote R, Simon J, Papo T: Reactive hemophagocytic syndrome in adult systemic disease: report of twenty-six cases and literature review. Arthritis Rheum. 2003, 49: 633-639. 10.1002/art.11368.CrossRefPubMed
4.
go back to reference Henter JI, Horne A, Aricó M: HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007, 48: 124-131. 10.1002/pbc.21039.CrossRefPubMed Henter JI, Horne A, Aricó M: HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007, 48: 124-131. 10.1002/pbc.21039.CrossRefPubMed
5.
go back to reference Filipovich AH: Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program. 2009, 127-131. Filipovich AH: Hemophagocytic lymphohistiocytosis (HLH) and related disorders. Hematology Am Soc Hematol Educ Program. 2009, 127-131.
6.
Metadata
Title
The significance of 18F-FDG PET/CT in secondary hemophagocytic lymphohistiocytosis
Authors
Li-Juan Zhang
Ji Xu
Peng Liu
Chong-Yang Ding
Jian-Yong Li
Hong-Xia Qiu
Su-Jiang Zhang
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Hematology & Oncology / Issue 1/2012
Electronic ISSN: 1756-8722
DOI
https://doi.org/10.1186/1756-8722-5-40

Other articles of this Issue 1/2012

Journal of Hematology & Oncology 1/2012 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine